Toyoki Daigo, Shibata Shigeru, Kuribayashi-Okuma Emiko, Xu Ning, Ishizawa Kenichi, Hosoyamada Makoto, Uchida Shunya
Division of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan; and.
Division of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan; and
Am J Physiol Renal Physiol. 2017 Sep 1;313(3):F826-F834. doi: 10.1152/ajprenal.00012.2017. Epub 2017 Jul 5.
Accumulating data indicate that renal uric acid (UA) handling is altered in diabetes and by hypoglycemic agents. In addition, hyperinsulinemia is associated with hyperuricemia and hypouricosuria. However, the underlying mechanisms remain unclear. In this study, we aimed to investigate how diabetes and hypoglycemic agents alter the levels of renal urate transporters. In insulin-depleted diabetic rats with streptozotocin treatment, both UA excretion and fractional excretion of UA were increased, suggesting that tubular handling of UA is altered in this model. In the membrane fraction of the kidney, the expression of urate transporter 1 (URAT1) was significantly decreased, whereas that of ATP-binding cassette subfamily G member 2 (ABCG2) was increased, consistent with the increased renal UA clearance. Administration of insulin to the diabetic rats decreased UA excretion and alleviated UA transporter-level changes, while sodium glucose cotransporter 2 inhibitor (SGLT2i) ipragliflozin did not change renal UA handling in this model. To confirm the contribution of insulin in the regulation of urate transporters, normal rats received insulin and separately, ipragliflozin. Insulin significantly increased URAT1 and decreased ABCG2 levels, resulting in increased UA reabsorption. In contrast, the SGLT2i did not alter URAT1 or ABCG2 levels, although blood glucose levels were similarly reduced. Furthermore, we found that insulin significantly increased endogenous URAT1 levels in the membrane fraction of NRK-52E cells, the kidney epithelial cell line, demonstrating the direct effects of insulin on renal UA transport mechanisms. These results suggest a previously unrecognized mechanism for the anti-uricosuric effects of insulin and provide novel insights into the renal UA handling in the diabetic state.
越来越多的数据表明,糖尿病及降糖药物会改变肾脏对尿酸(UA)的处理。此外,高胰岛素血症与高尿酸血症和低尿酸尿症相关。然而,其潜在机制仍不清楚。在本研究中,我们旨在探究糖尿病和降糖药物如何改变肾脏尿酸转运蛋白的水平。在用链脲佐菌素治疗的胰岛素缺乏型糖尿病大鼠中,UA排泄及UA分数排泄均增加,这表明该模型中肾小管对UA的处理发生了改变。在肾脏的膜组分中,尿酸转运蛋白1(URAT1)的表达显著降低,而ATP结合盒转运体G超家族成员2(ABCG2)的表达增加,这与肾脏UA清除率增加一致。给糖尿病大鼠注射胰岛素可降低UA排泄,并减轻UA转运蛋白水平的变化,而钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)依帕列净在该模型中并未改变肾脏对UA的处理。为证实胰岛素在尿酸转运蛋白调节中的作用,正常大鼠分别接受胰岛素和依帕列净。胰岛素显著增加URAT1水平并降低ABCG2水平,导致UA重吸收增加。相比之下,尽管血糖水平同样降低,但SGLT2i并未改变URAT1或ABCG2水平。此外,我们发现胰岛素显著增加了肾上皮细胞系NRK-52E细胞膜组分中内源性URAT1水平,证明了胰岛素对肾脏UA转运机制的直接作用。这些结果提示了一种此前未被认识的胰岛素抗尿酸尿作用机制,并为糖尿病状态下肾脏对UA的处理提供了新的见解。